NCT04970004

Study in Adult and Pediatric Patients With HSCT-TMA

A Retrospective Observational Study of Adult and Pediatric Patients With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: Alexion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 1 Month
• Healthy volunteers: Not accepted

Summary

This is an observational, retrospective study designed to assess outcomes in patients diagnosed with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) who were not treated with complement component (C5) inhibitor therapy. Data required to evaluate study outcomes will be abstracted from the medical records of all patients who meet study eligibility criteria.

Conditions

• Stem Cell Transplant Complications
• Thrombotic Microangiopathies

Interventions

Type	Name	Description
OTHER	No intervention	No study intervention will be administered as part of this study.

Timeline

• Start date: 2021-07-12
• Primary completion: 2022-04-01
• Completion: 2022-04-01
• First posted: 2021-07-21
• Last updated: 2022-05-12

Locations

1 site across 1 country: United States